Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Oxford University, through its innovation arm Oxford University Innovation (OUI), has entered into an option agreement for a universal influenza vaccine with US-based startup Blue Water Vaccines (BWV), which is raising $15m to support development of the flu shot.

3D rendering of microscopic virus in front of abstract background © Shutterstock

Developed by scientists at the University’s Department of Zoology the vaccine protects against all influenza strains by targeting parts of the virus that induce a protective immune response but are also limited in variability. The technology has the potential of providing life-long immunity against flu.

Influenza is a major respiratory pathogen. It is estimated that there are over almost 500,000 deaths a year caused by influenza, with somewhere between three to five million severe cases of illness annually. The virus is estimated to cost $87.1bn in absenteeism in the US alone. Current influenza vaccines target highly variable epitopes of the virus which evolve and change annually, meaning flu vaccines need to be updated and redistributed every season while only typically providing protection to 50% of the individuals who receive it. Conversely, the universal flu vaccine developed at Oxford University targets epitopes that are both naturally immunogenic and limited in variability, allowing for a vaccine that protects against all influenza strains and avoids the need to be regularly updated.

Read more (University of Oxford website)

Similar stories

Oxford spinout MiroBio acquired by Gilead Sciences for $405m

The inflammatory diseases company’s rapid ascent and exit underscores the importance of friendships, partnerships and networks in innovation.

Viral role in Alzheimer's Disease discovered

Researchers from Oxford’s Institute of Population Ageing, Tufts University and the University of Manchester have discovered that common viruses appear to play a role in some cases of Alzheimer’s disease (AD).

Researchers develop new breath-driven concept set to transform access to hand prosthetics

The new air-powered hand provides a lightweight, low-maintenance and easy-to-use body-powered prosthetic option particularly well suited for children and those in low and middle-income countries.

Professor Hugh Watkins wins £30 million research award to cure killer heart diseases

The British Heart Foundation award aims to help researchers rewrite DNA, in “defining moment” for cardiovascular medicine.

New rabies vaccine candidate demonstrates promising immune response and safety

Researchers from the University of Oxford have today reported new findings from a Phase 1 clinical trial studying the immune response and safety of their newly-developed single shot rabies vaccine, ChAdOx2 RabG - with promising results identified.

Gaming does not appear harmful to mental health, unless the gamer can't stop - Oxford study

Societies may tremble when a hot new video game is released, but the hours spent playing popular video games do not appear to be damaging players’ mental health, according to the largest-ever survey of nearly 40,000 gamers and their gaming habits, which was conducted over six weeks by a team from Oxford’s Internet Institute. That does not mean, however, that the research did not throw up some concerns – and, the team argues, much more information is needed before tech regulators, can really rest easy.